Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Symmetry Medical overstated revenues

This article was originally published in The Gray Sheet

Executive Summary

Orthopedic device firm's Sheffield, UK unit may have overstated revenue by $24 million to $28 million since 1999 or before, nearly double the $12 million to $16 million the firm previously estimated, the company says Nov. 12. The senior VP for Europe and other employees at the unit were believed to be involved in the financial reporting problems, Symmetry Medical said when it first announced the issue Oct. 4. The Warsaw, Ind.-based firm acquired the Sheffield business in June 2003. CEO Brian Moore maintains that so far the problem involves the UK operations only. While the company may need to restate financial statements filed since 2003, it does not expect a material effect on previously reported 2007 sales or earnings. Symmetry Medical's board continues to investigate the matter

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025508

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel